Dr. Azad on Third-Line Treatment Options in CRC

Nilofer S​aba Azad, MD, associate professor of oncology, Johns Hopkins ​University School of Medicine, ​director, Developmental Therapeutics Clinical Trials Program, Johns Hopkins Sidney Kimmel Cancer Center, discusses third-line treatment options for patients with colorectal cancer (CRC).

Patients with KRAS wild-type CRC can receive EGFR inhibitors, Azad says.

Additionally, patients whose tumors harbor a BRAF mutation should be treated with a BRAF inhibitor in combination with an EGFR inhibitor, explains Azad.

For the general population of patients with CRC, treatment selection is between TAS-102 (trifluridine/tipiracil; Lonsurf) and regorafenib (Stivarga) in the third-line setting, concludes Azad.